Replies to post #332258 on Avid Bioservices Inc (CDMO)

[vinmantoo]

Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled "Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses" at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.

That has NOTHING to do with Bavi.

CDMO doesn't own phosphatidylserine and it doesn't own receptors that might interact with PS as part of its mechanism of function. I explained several times why PS is a VERY POOR target for oncology as it is found in massive numbers when exposed including a tremendous sink of exposed PS on apoptotic cells that will titrate aways anti-PS antibodies. That is likely why Bavi has never succeeded in a controlled trial and why Bavi was given away for a song to a startup Chinese company. Cellular receptors that may interact with PS on cancer cells are found in orders of magnitudes lower levels than PS so represents far more prosing targets.

It gets tiresome having to repeat this.